Friday, October 25, 2013

WHO Middle East respiratory syndrome coronavirus (MERS-CoV) - update October 24, 2013

The National Health and Family Planning Commission, China notified WHO of a new laboratory-confirmed case of human infection with avian influenza A(H7N9) virus.
The patient is a 67-year-old man from Zhejiang Province. He is a farmer, and has had contact with live poultry. He became ill on 16 October 2013, was admitted to a local township hospital on 18 October 2013, and was transferred to another hospital on 21 October 2013 as his condition deteriorated. He is currently in a critical condition.
To date, WHO has been informed of a total of 137 laboratory-confirmed human cases with avian influenza A(H7N9) virus infection including 45 deaths. Currently, four patients are hospitalized and 88 have been discharged. So far, there is no evidence of sustainable human-to-human transmission.
The Chinese government has taken the following surveillance and control measures:
  • strengthening of epidemic surveillance and analysis;
  • deployment of medical treatment;
  • conducting public risk communication and information dissemination;
  • strengthening international cooperation and exchanges; and
  • is continuing to carry out scientific research.
WHO does not advise special screening at points of entry with regard to this event, nor does it currently recommend any travel or trade restrictions. 

http://www.who.int/csr/don/2013_10_24a/en/index.html 

WHO Middle East respiratory syndrome coronavirus (MERS-CoV) - update October 24, 2013




WHO has been informed of two laboratory-confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection in Saudi Arabia on 18 and 19 October 2013, and three laboratory-confirmed cases on 18 September 2013.
Of the five laboratory-confirmed cases, two died. The ages of the five patients range from 35 to 83 years old; four men and one woman; two from Medinah and three Riyadh. Four patients had underlying medical conditions. Two patients reported having no contact with a laboratory-confirmed case or with animals prior to becoming ill. 

Globally, from September 2012 to date, WHO has been informed of a total of 144 laboratory-confirmed cases of infection with MERS-CoV, including 62 deaths.
Based on the current situation and available information, WHO encourages all Member States to continue their surveillance for severe acute respiratory infections (SARI) and to carefully review any unusual patterns. 

Health care providers are advised to maintain vigilance. Recent travellers returning from the Middle East who develop SARI should be tested for MERS-CoV as advised in the current surveillance recommendations.
Patients diagnosed and reported to date have had respiratory disease as their primary illness. Diarrhoea is commonly reported among the patients and severe complications include renal failure and acute respiratory distress syndrome (ARDS) with shock. It is possible that severely immunocompromised patients can present with atypical signs and symptoms.
Health care facilities are reminded of the importance of systematic implementation of infection prevention and control (IPC). Health care facilities that provide care for patients suspected or confirmed with MERS-CoV infection should take appropriate measures to decrease the risk of transmission of the virus to other patients, health care workers and visitors.
All Member States are reminded to promptly assess and notify WHO of any new case of infection with MERS-CoV, along with information about potential exposures that may have resulted in infection and a description of the clinical course. Investigation into the source of exposure should promptly be initiated to identify the mode of exposure, so that further transmission of the virus can be prevented.
WHO does not advise special screening at points of entry with regard to this event nor does it currently recommend the application of any travel or trade restrictions.
WHO has convened an Emergency Committee under the International Health Regulations (IHR) to advise the Director-General on the status of the current situation. The Emergency Committee, which comprises international experts from all WHO Regions, unanimously advised that, with the information now available, and using a risk-assessment approach, the conditions for a Public Health Emergency of International Concern (PHEIC) have not at present been met.

http://www.who.int/csr/don/2013_10_24/en/index.html 

Monday, October 21, 2013

#MERS #Coronavirus Saudi Arabia Dr. Memish: Pilgrims' Health Status Is Reassuring...No Epidemic Cases Detected

16 October 2013

The Deputy Minister for Public Health and the Head of the Hajj Curative Medicine Committee, Dr. Ziad bin Ahmed Memish, said that the health situation is reassuring, and there are no epidemic diseases among pilgrims thankfully so far.
 
In addition, the Ministry of Health (MOH) has not yet recorded any cases of meningitis or food poisoning in the Holy Sites, expressing his hope that the health situation continues as it is now so that the pilgrimage season passes safely without recording any epidemic or quarantine diseases.
 
Within the same vein, Dr. Memish announced at a news conference held on Tuesday that the Kingdom has updated its health requirements this year after following up and monitoring the global heath situation throughout the year in collaboration with the World Health Organization (WHO) and the research and diseases centers in America and Europe.
 
In addition, Dr. Memish underscored that the MOH has launched a huge awareness campaign targeting the countries from which the pilgrims come, adding that such campaigns focus on the pilgrimage ports and areas; contributing significantly to obtaining such good fruits so far.
 
Within the same vein, Dr. Memish pointed out that based upon the MOH’s accumulated experiences and study of cases with Coronavirus, the Ministry advices the elderly people, patients with chronic diseases, pregnant women and children to postpone the performance of Hajj, after founding that 75% of the Coronavirus deaths which are recorded locally and globally occur amidst such segments of people.
 
Moreover, Dr. Memish underscored that the Ministry is currently working on preparation and implementation of 10 studies expected to help in dealing with the pilgrims and contributing to the development of solutions to any emergent health problems, especially the infectious and epidemic diseases which attract the attention of the Ministry, noting that some of such studies are related to Coronavirus while others are related to meningitis and the other viruses widely spread in the world.
 
Furthermore, Dr. Memish mentioned that the study teams have ended the first phase, during which random samples were taken from pilgrims coming from abroad, noting that the second phase will kick off on Thursday 12/12/1434H (corresponding to 17/10/2013) by taking samples from the pilgrims before their departure to make sure that they are free from diseases and to recognize their health status.
 
Speaking of the ways of dealing with any Coronavirus case, Allah forbid, Dr. Memish said that the Ministry has a several-phase plan to face these potential cases; such a plan starts with diagnosing the case and testing the health practitioners, with isolation of the positive cases in rooms allocated for this purpose and examination of the close people, pointing out that the laboratories have already been equipped with equipments.

http://www.moh.gov.sa/en/Ministry/MediaCenter/News/Pages/news-2013-10-16-005.aspx

Flu virus wipes out immune system’s first responders to establish infection

Hat-tip:  Flutrackers.com
October 19, 2013

CAMBRIDGE, Mass. – Revealing influenza’s truly insidious nature, Whitehead Institute scientists have discovered that the virus is able to infect its host by first killing off the cells of the immune system that are actually best equipped to neutralize the virus.

Confronted with a harmful virus, the immune system works to generate cells capable of producing antibodies perfectly suited to bind and disarm the hostile invader. These virus-specific B cells proliferate, secreting the antibodies that slow and eventually eradicate the virus. A population of these cells retains the information needed to neutralize the virus and takes up residence in the lung to ward off secondary infection from re-exposure to the virus via inhalation.
On the surface of these so-called memory B cells are high-affinity virus-specific receptors that bind virus particles to reduce viral spread. While such cells should serve at the body’s first line of defense, it turns out that flu virus exploits the specificity of the cells’ receptors, using them to gain entry, disrupt antibody production, and ultimately kill the cells. By dispatching its enemies in this fashion, the virus is able to replicate efficiently before the immune system can mount a second wave of defense. This seemingly counter-intuitive pathway to infection is described this week in the journal Nature.

“We can now add this to the growing list of ways that the flu virus has to establish infection,” says Joseph Ashour, a co-author of the Nature paper and a postdoctoral researcher in the lab of Whitehead Member Hidde Ploegh.
“This is how the virus gains a foothold,” adds Ploegh lab postdoc Stephanie Dougan, also a co-author of the study. “The virus targets memory cells in the lung, which allows infection to be established—even if the immune system has seen this flu before.”

Continued:  http://wi.mit.edu/news/archive/2013/flu-virus-wipes-out-immune-system-s-first-responders-establish-infection

Saturday, October 19, 2013

World Health Organization (WHO): Saudi Arabia has succeeded in protecting the 1.5 million pilgrims from the #coronavirus #MERS & epidemic diseases

October 19, 2013
Translation

Said Dr Ala Din Alwan , director of the Eastern Mediterranean Region , World Health Organization ( WHO ) that the Saudi authorities succeeded in preventing the spread of epidemics and viruses private Coruna center of more than 1.5 million pilgrims during the Hajj season .
The announcement came ahead of Alwan leave Cairo on Saturday on his way to Amman to participate in some activities of the regional organization.
Said Alwan : " WHO participated in monitoring the health status of the pilgrims through some observers and observers did not monitor any cases of epidemic or cases of HIV Coruna among the pilgrims so far , with no surveillance of our units are any cases of the virus Corona or serious diseases threaten the safety of pilgrims and has provided authorities Saudi Arabia and health services adequately in each ritual sites and has developed several health points and medical centers in the holy sites in Mina . "
He added: " WHO was worried about the spread of Corona and some epidemics amid pilgrims this season was sent teams of software epidemic diseases to participate in a technical mission to monitor , guide and advise on precautionary measures to prevent the spread of Corona and assist in the early detection of the spread of the epidemic , but the performance of the authorities Saudi Arabia has succeeded in protecting both the number of pilgrims from the spread of epidemics season so far passed an unprecedented rate of success health . "


http://gate.ahram.org.eg/News/407347.aspx 

Friday, October 18, 2013

#MERS #Coronavirus WHO Update October 18, 2013

Middle East respiratory syndrome coronavirus (MERS-CoV) - update

WHO has been informed of an additional laboratory-confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection in Qatar.
The patient is a 61-year-old man with underlying medical conditions who was admitted to a hospital on 11 October 2013. He is currently hospitalized and is in a stable condition. The patient was tested positive for MERS-CoV infection in Qatar and was confirmed by the reference laboratory of Public Health England yesterday.
Preliminary investigations revealed that the patient had not travelled outside Qatar in the two weeks prior to becoming ill. The patient owns a farm and has had significant contact with the animals, including camels, sheep and hens. Some of the animals in his farm have been tested and were negative for MERS-CoV. Further investigations into the case and the animals in the farm are ongoing. 

Globally, from September 2012 to date, WHO has been informed of a total of 139 laboratory-confirmed cases of infection with MERS-CoV, including 60 deaths.
Based on the current situation and available information, WHO encourages all Member States to continue their surveillance for severe acute respiratory infections (SARI) and to carefully review any unusual patterns.
Health care providers are advised to maintain vigilance. Recent travellers returning from the Middle East who develop SARI should be tested for MERS-CoV as advised in the current surveillance recommendations.
Specimens from patients’ lower respiratory tracts should be obtained for diagnosis where possible. Clinicians are reminded that MERS-CoV infection should be considered even with atypical signs and symptoms, such as diarrhoea, in patients who are immunocompromised.
Health care facilities are reminded of the importance of systematic implementation of infection prevention and control (IPC). Health care facilities that provide care for patients suspected or confirmed with MERS-CoV infection should take appropriate measures to decrease the risk of transmission of the virus to other patients, health care workers and visitors.
All Member States are reminded to promptly assess and notify WHO of any new case of infection with MERS-CoV, along with information about potential exposures that may have resulted in infection and a description of the clinical course. Investigation into the source of exposure should promptly be initiated to identify the mode of exposure, so that further transmission of the virus can be prevented.
WHO does not advise special screening at points of entry with regard to this event nor does it currently recommend the application of any travel or trade restrictions.
WHO has convened an Emergency Committee under the International Health Regulations (IHR) to advise the Director-General on the status of the current situation. The Emergency Committee, which comprises international experts from all WHO Regions, unanimously advised that, with the information now available, and using a risk-assessment approach, the conditions for a Public Health Emergency of International Concern (PHEIC) have not at present been met.

http://www.who.int/csr/don/2013_10_18/en/index.html 

Wednesday, October 16, 2013

#H7N9 WHO: Human infection with avian influenza A(H7N9) virus – update 10/16/13

The National Health and Family Planning Commission, China notified WHO of a new laboratory-confirmed case of human infection with avian influenza A(H7N9) virus. This is the first new confirmed case of human infection with avian influenza A(H7N9) virus since 11 August 2013.

The patient is a 35-year-old man from Zhejiang Province. He was admitted to a hospital on 8 October 2013 and is in a critical condition. Additionally, a previously laboratory-confirmed patient from Hebei has died.

To date, WHO has been informed of a total of 136 laboratory-confirmed human cases with avian influenza A(H7N9) virus infection including 45 deaths. Currently, three patients are hospitalized and 88 have been discharged. So far, there is no evidence of sustainable human-to-human transmission. 

The Chinese government continues to take strict monitoring, prevention and control measures, including: strengthening of epidemic surveillance and analysis; deployment of medical treatment; conducting public risk communication and information dissemination; strengthening international cooperation and exchanges; and is continuing to carry out scientific research.
WHO does not advise special screening at points of entry with regard to this event, nor does it currently recommend any travel or trade restrictions. 

http://www.who.int/csr/don/2013_10_16/en/index.html 

Tuesday, October 15, 2013

INFLUENZA (58): WORLD HEALTH ORGANIZATION GLOBAL UPDATE NO.196

A ProMED-mail post
Date: Mon 14 Oct 2013
Source: WHO surveillance & monitoring update 196 [edited]
http://www.who.int/influenza/surveillance_monitoring/updates/2013_10_14_surveillance_update_196.pdf


Influenza Update No. 196 - 14 Oct 2013
--------------------------------------
Summary

Although in many European countries influenza-like illness activity started to increase, influenza activity in the northern hemisphere temperate zones remained at inter-seasonal levels.

In most regions of tropical Asia, influenza activity was at a low level, with the exception of Hong Kong Special Administrative Region, China, where influenza transmission increased due to influenza A(H3N2).

In the Caribbean region of Central America and tropical South American countries, cases of influenza decreased, while acute respiratory illness remained stable in the Caribbean and Central America. Respiratory syncytial virus (RSV) predominated, but the RSV activity remained within expected seasonal levels.

Influenza activity peaked in the temperate countries of South America and in South Africa in late June 2013. Temperate South American countries reported acute respiratory disease activity within expected seasonal levels, and RSV activity largely declined.

In Australia and New Zealand, numbers of influenza viruses detected and rates of influenza-like illness seemed to have peaked. Co-circulation of influenza A(H1N1)pdm09, A(H3N2) and B viruses was reported in both countries.

Additional and updated information on non-seasonal influenza viruses can be found at: http://who.int/influenza/human_animal_interface/HAI_Risk_Assessment/en/inde.

Countries in the temperate zone of the northern hemisphere
--------------------------------
North America
Overall influenza activity in North America remained at low levels throughout the region. In Canada and the United States of America, influenza activity remained at interseasonal levels. In Mexico, influenza activity remained low after a period of 2 months (July-August 2013) with higher influenza activity.

Europe
Influenza activity in Europe remained at interseasonal levels. None of the specimens collected from sentinel sites between 10-22 Sep 2013 tested positive for influenza. However, many countries started reporting increased consultation rates for influenza-like illness (ILI) and acute respiratory infection (ARI).

Northern Africa and the Western Asia region
Influenza activity was low in the Northern Africa and western Asia regions. Only Qatar reported influenza activity, mainly influenza A virus (not subtyped), since the end of August 2013.

Northern Asia
Influenza activity in the temperate region of Asia remained at interseasonal levels since late May 2013. In Mongolia, clinical activity started to increase since mid-August 2013, but no influenza viruses were detected in this period.

Countries in the tropical zone
-----------------------
Tropical countries of the Americas/Central America and the Caribbean:

Overall influenza activity in the Caribbean and Central America was at a low level throughout the region. Decreasing numbers of influenza A virus have been seen throughout the region, but influenza transmission had largely come to an end in the last few weeks in these countries. Co-circulation of influenza A(H3N2) and influenza B viruses were reported, and RSV predominated among respiratory viruses in Costa Rica, El Salvador, Nicaragua, and Panama.

In tropical South America, respiratory virus activity continued decreasing following a period of high influenza activity in July and August 2013. In Colombia, the proportions of outpatient visits, hospitalizations, and ICU admissions were similar to reports for the same period in previous years. In Venezuela, ARI and pneumonia levels were reported within the expected values for the time of year. In Ecuador, the number of positive influenza samples steadily decreased since its influenza peak in August 2013. In Peru, reports of ARI in children under 5 years of age have been increasing since July 2013, but were consistent with levels from previous years. In the Plurinational State of Bolivia, the proportion of SARI-related hospitalizations were reported as elevated compared to the data from the same period last year [2012], and laboratory data from CENETROP [National Center of Tropical and Infectious Diseases] in Santa Cruz showed that of 182 SARI samples analyzed in the beginning of October 2013, 33 percent were positive for a respiratory virus (a 9 percent increase from the previous week). Brazil showed a continuing decline in the number of positive influenza samples since July 2013, and among recent positive samples, influenza A un-typed and influenza B viruses were detected.

Central African tropical region
Cote d'Ivoire, Ghana, and Kenya reported circulating influenza viruses. In Cote d'Ivoire and Ghana, influenza B and A(H3N2) were the predominant viruses detected. Kenya reported low influenza activity due to both influenza A(H3N2) and influenza B viruses.

Tropical Asia
Influenza transmission in southern and Southeast Asia was low in most countries. Both influenza A(H1N1)pdm09 and A(H3N2) viruses were reported in this area. Since early July 2013, an increase in influenza transmission was seen in Hong Kong Special Administrative Region (SAR), China. The influenza transmission in Hong Kong SAR was predominated by influenza A(H3N2) virus. This increased transmission was also seen in the influenza associated hospital rates in this region; mainly the rates among 0-4-year-old patients increased over the past month. In the south of China, influenza activity remained at an interseasonal level. However, the number of influenza virus detections has been higher in this year's [2013] interseasonal period compared to the previous year.

Countries in the temperate zone of the southern hemisphere
-----------------------------------
Temperate countries of South America
In the temperate countries of South America, ARI activity was reported at expected levels for the time of year, and RSV continued to be the most common respiratory virus detected in Argentina and Chile, although cases had largely decreased. In Argentina, ILI activity continued its decreasing trend since its peak in June and July of this year [2013]. In Chile, the proportion of SARI-associated hospitalizations continued to decrease. In Paraguay, the ILI consultation rate was higher than expected for the time of year but with decreased influenza and respiratory virus detection. In Uruguay, the proportion of SARI-associated hospitalizations increased from levels reported in the previous week, but proportions of ICU admissions continued to decline.

Temperate countries of Southern Africa
After a peak in influenza activity in South Africa due to influenza A(H1N1)pmd09 in June 2013, a small 2nd peak was observed in the last few weeks due to increased influenza A(H3N2) and influenza B circulation.

Overall, in Australia, New Zealand, and the Pacific Islands, influenza activity seemed to have peaked.

In Australia, during the period from 30 Aug to 13 Sep 2013, the distribution of influenza types and subtypes was variable across jurisdictions. In Western Australia, influenza A(H3N2) remained the predominant virus subtype; however, the proportion of A(H1N1)pdm09 increased. Influenza type B continued to represent over half of Victoria's influenza notifications. In recent weeks, there have been increasing proportions of influenza B virus in Queensland and South Australia. Influenza positivity levels ranged from 15 percent (309/2114) in the national sentinel laboratory surveillance to 28.1 percent (56/199) in the Australian Sentinel Practices Research Network (ASPREN). The Influenza Complications Alert Network (FluCAN) sentinel hospital surveillance system reported that the rate of influenza associated hospitalisations had been relatively stable since mid-August 2013. Almost 15 percent of influenza associated hospitalisations were admitted directly to the ICU. The age distribution of hospital admissions showed peaks in the 0-9 and over 60 years age groups.

In New Zealand, ILI activity was almost at the baseline threshold in early September 2013 but decreased since then. Out of 303 samples received in the last week, 161 were positive for influenza (53 percent): 49 were influenza B, 16 were influenza A(H3N2), 22 were influenza A(H1N1)pdm09, and 74 were influenza A (not subtyped). In Auckland and Counties Manukau District Health Boards, decreased influenza activity was reported in community surveillance and hospital surveillance.

http://www.promedmail.org/direct.php?id=20131015.2003667

#MERS #Coronavirus WHO Update October 14, 2013

WHO has been informed of an additional two laboratory-confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection in Saudi Arabia.
The patients, both men, aged 55 and 78, were from Riyadh region. They became ill at the end of September 2013 and died in the beginning of October 2013. Both the patients were reported to have had no contact to a known laboratory-confirmed case with MERS-CoV.
Globally, from September 2012 to date, WHO has been informed of a total of 138 laboratory-confirmed cases of infection with MERS-CoV, including 60 deaths.
Based on the current situation and available information, WHO encourages all Member States to continue their surveillance for severe acute respiratory infections (SARI) and to carefully review any unusual patterns.
Health care providers are advised to maintain vigilance. Recent travellers returning from the Middle East who develop SARI should be tested for MERS-CoV as advised in the current surveillance recommendations.
Specimens from patients’ lower respiratory tracts should be obtained for diagnosis where possible. Clinicians are reminded that MERS-CoV infection should be considered even with atypical signs and symptoms, such as diarrhoea, in patients who are immunocompromised.
Health care facilities are reminded of the importance of systematic implementation of infection prevention and control (IPC). Health care facilities that provide care for patients suspected or confirmed with MERS-CoV infection should take appropriate measures to decrease the risk of transmission of the virus to other patients, health care workers and visitors.
All Member States are reminded to promptly assess and notify WHO of any new case of infection with MERS-CoV, along with information about potential exposures that may have resulted in infection and a description of the clinical course. Investigation into the source of exposure should promptly be initiated to identify the mode of exposure, so that further transmission of the virus can be prevented.
WHO does not advise special screening at points of entry with regard to this event nor does it currently recommend the application of any travel or trade restrictions.
WHO has convened an Emergency Committee under the International Health Regulations (IHR) to advise the Director-General on the status of the current situation. The Emergency Committee, which comprises international experts from all WHO Regions, unanimously advised that, with the information now available, and using a risk-assessment approach, the conditions for a Public Health Emergency of International Concern (PHEIC) have not at present been met.

http://www.who.int/csr/don/2013_10_14/en/index.html 

Monday, October 14, 2013

Adaptive evolution of bat dipeptidyl peptidase 4 (dpp4): implications for the origin and emergence of Middle East respiratory syndrome coronavirus

Virology Journal 2013, 10:304 doi:10.1186/1743-422X-10-304
Published: 10 October 2013

Abstract (provisional)

Background

The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) that first appeared in Saudi Arabia during the summer of 2012 has to date (20th September 2013) caused 58 human deaths. MERS-CoV utilizes the dipeptidyl peptidase 4 (DPP4) host cell receptor, and analysis of the long-term interaction between virus and receptor provides key information on the evolutionary events that lead to the viral emergence.
Findings We show that bat DPP4 genes have been subject to significant adaptive evolution, suggestive of a long-term arms-race between bats and MERS related CoVs. In particular, we identify three positively selected residues in DPP4 that directly interact with the viral surface glycoprotein.

Conclusions

Our study suggests that the evolutionary lineage leading to MERS-CoV may have circulated in bats for a substantial time period.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production. 

http://www.virologyj.com/content/10/1/304/abstract 



Thursday, October 10, 2013

#MERS #Coronavirus Saudi Arabia Announces Absense of Virus among Pilgrims

Mecca, 10/10/2013 (AFP) - The Saudi Health Minister Abdullah Al-Rabiah not record any injury Corona virus among pilgrims who start next Sunday pilgrimage.
Al-Riyadh newspaper quoted Rabiah as saying that the health status of pilgrims "reassuring as it is not registered any case of epidemic or Mahgria including the Corona virus."
He stressed that "the ministry is very keen to follow up on the epidemiological situation in the countries of the world, in coordination with the World Health Organization and put crack down this year with a virus Corona, and give workers strict instructions to isolate any suspected case out and conduct the necessary tests to ensure their safety."
Rabiah said that there is a team of 600 employees of the ministry in the King Abdul Aziz Airport provide curative and preventive services in full coordination with the parties participating in the pilgrimage all.
And puts workers at Jeddah airport masks for Okabh of the Corona virus, which killed 58 victims in the world so far, including 49 in Saudi Arabia, where he appeared for the first time.
The World Health Organization announced last Friday that the number of people infected with the virus of 136 people, including 117 in Saudi Arabia.
And overshadowed by fears of the spread of Corona during the pilgrimage season, the largest religious gathering of Muslims in the world.
However, the Minister of Health was expressed optimism gap in the pilgrimage season of the virus in the absence of any registration injury Umrah season.
But he called the elderly, the infirm and people with chronic illnesses to avoid coming to the pilgrimage this year.



Wednesday, October 9, 2013

#MERS #Coronavirus Saudi Arabia MOH Update 10/9/13

October 9, 2013
Translation

 
In the framework of the epidemiological investigation and ongoing follow-up carried out by the Ministry of Health for HIV (Corona) new syndrome that causes 
Middle East of MERS-CoV respiratory ministry announces the registration of two cases in the Riyadh region.
First of a citizen at the age of 78 years old, suffers from several chronic diseases, has died of God's mercy. 
The second case to another citizen at the age of 55 years old and suffering from chronic diseases, has died God's mercy. 
http://www.moh.gov.sa/CoronaNew/PressReleases/Pages/mediastatemenet-2013-10-09-001.aspx

Monday, October 7, 2013

Pandemic Preparedness: Taking Our Cue From The Experts

A very good read full of resources, from Avian Flu Diary:

http://afludiary.blogspot.com/2013/10/pandemic-preparedness-taking-our-cue.html

ProMED: CHINA, H7N9 LOW TRANSMISSION POTENTIAL

Published Date: 2013-10-05 13:28:47
Subject: PRO/AH> Avian influenza, human (118): China, H7N9 low transmission potential
Archive Number: 20131005.1982621

Date: Wed 2 Oct 2013
Source: University of Minnesota Center for Infectious Disease Research and Policy (CIDRAP) [edited]
http://www.cidrap.umn.edu/news-perspective/2013/10/flu-scan-oct-02-2013


Researchers who used a sophisticated modeling approach incorporating H7N9 case data from China found hints that the virus has low transmission potential and that the pace of infection slowed in April [2013] after officials closed live-bird markets. The study, published in BMC Medicine today [2 Oct 2013], was conducted by a team from the National Institutes of Health, Arizona State University, and George Washington University.

The investigators used a Bayesian modeling technique [see http://en.wikipedia.org/wiki/Bayesian_statistics] to assess if the outbreak had a reproduction (R) number consistent with unsustained human transmission and if interventions reduced transmission. They compared their estimates with other zoonotic pathogens, including H5N1 avian influenza, variant H3N2 (H3N2v) influenza flu, and Nipah virus. Based on 130 lab-confirmed cases reported in China from March through 20 May 2013, their analysis found that transmission was low in Shanghai and Zhejiang province, and at 0.6 the R was well below the 1.0 level needed to sustain transmission. Researchers also found that the growth rate slowed in mid April [2013], which coincided with the closure of live-bird markets in large Chinese cities in early April. Compared with other zoonotic threats, the transmission threat from H7N9 was lower.

The authors said that, although the findings were based on a small number of cases and need to be confirmed, the modeling technique could be useful for measuring outbreak progression and the impact of control measures in the months ahead and provides a tool for monitoring pandemic potential in near real-time.

--
Communicated by:
ProMED-mail
<promed@promedmail.org>

[The reference for the BMC Medicine paper is: Transmission potential of influenza A/H7N9, February to May 2013, China; by Gerardo Chowell, Lone Simonsen, Sherry Towers, Mark A Miller and Cecile Viboud; in BMC Medicine 2013, 11:214 doi:10.1186/1741-7015-11-214; http://www.biomedcentral.com/1741-7015/11/214/abstract. The Abstract follows.

"Background: On 31 Mar 2013, the 1st human infections with the novel influenza A/H7N9 virus were reported in Eastern China. The outbreak expanded rapidly in geographic scope and size, with a total of 132 laboratory-confirmed cases reported by 3 Jun 2013, in 10 Chinese provinces and Taiwan [imported from mainland China]. The incidence of A/H7N9 cases has stalled in recent weeks, presumably as a consequence of live bird market closures in the most heavily affected areas. Here we compare the transmission potential of influenza A/H7N9 with that of other emerging pathogens and evaluate the impact of intervention measures in an effort to guide pandemic preparedness.

Methods: We used a Bayesian approach combined with a SEIR (Susceptible-Exposed-Infectious-Removed) transmission model fitted to daily case data to assess the reproduction number (R) of A/H7N9 by province and to evaluate the impact of live bird market closures in April and May 2013. Simulation studies helped quantify the performance of our approach in the context of an emerging pathogen, where human-to-human transmission is limited and most cases arises from spillover events. We also used alternative approaches to estimate R based on individual-level information on prior exposure and compared the transmission potential of influenza A/H7N9 with that of other recent zoonoses.

Results: Estimates of R for the A/H7N9 outbreak were below the epidemic threshold required for sustained human-to-human transmission and remained near 0.1 throughout the study period, with broad 95 percent credible intervals by the Bayesian method (0.01 to 0.49). The Bayesian estimation approach was dominated by the prior distribution, however, due to relatively little information contained in the case data. We observe a statistically significant deceleration in growth rate after 6 Apr 2013, which is consistent with a reduction in A/H7N9 transmission associated with the preemptive closure of live bird markets. Although confidence intervals are broad, the estimated transmission potential of A/H7N9 appears lower than that of recent zoonotic threats, including avian influenza A/H5N1, swine influenza H3N2sw and Nipah virus.

Conclusion: Although uncertainty remains high in R estimates for H7N9 due to limited epidemiological information, all available evidence points to a low transmission potential. Continued monitoring of the transmission potential of A/H7N9 is critical in the coming months as intervention measures may be relaxed and seasonal factors could promote disease transmission in colder months."

This analysis is consistent with independent studies, and a resurgence of disease should not occur unless there is some significant modification of the genetic properties of the H7N9 virus, or relaxation of the restrictions introduced to control access to poultry markets. - Mod.CP]

http://www.promedmail.org/direct.php?id=20131005.1982621

Thursday, October 3, 2013

#MERS #Coronavirus Saudi Arabia MOH Update October 1, 2013

October 1, 2013
In the framework of the epidemiological investigation and ongoing follow-up carried out by the Ministry of Health for HIV (Corona) that causes respiratory syndrome Middle East MERS-CoV. Ministry announces the registration of three cases of HIV infection in Riyadh.

First of a citizen at the age of 79 years is suffering from several chronic diseases, and Mkhalt of confirmed cases, and receives the necessary attention, and the second for citizenship at the age of 14 years, mixing with a confirmed case, too, and experiencing symptoms of a simple and health status is stable. The third is a citizen at the age of 45 years, Mkhalt to a confirmed case, suffering from chronic diseases, and receiving intensive care treatment. We ask God for their speedy recovery.

http://www.moh.gov.sa/CoronaNew/PressReleases/Pages/mediastatement-2013-10-01-001.aspx

Monday, September 30, 2013

Chinese CDC Issues Autumn Flu Warning

September 30, 2013

The Chinese Center for Disease Control and Prevention (China CDC) on Sunday warned of the likelihood that flu may spread from November.

The spread of the flu virus will peak in December and January, it forecast, adding that human migration and gathering in the upcoming week-long National Day holiday can also cause a spread of the virus.

The China CDC advised that precautions be taken, especially by schools, kindergartens, senior care homes, pregnant women, the elderly, infants and patients with chronic diseases.

The health watchdog suggested people lead a healthy lifestyle, enhance immunity and ensure ventilation in order to prevent flu and other respiratory diseases.
Vaccination is the most effective method to guard against flu, it added, suggesting pregnant women, seniors, babies, sufferers of chronic diseases and medical staff be vaccinated so as to enhance immunity.

Meanwhile, there have been no reports of human infection by H7N9 bird flu in the last two months, according to the CDC.

H7N9 cases in China reached 134 by the end of August, with the latest reported patient in south China's Guangdong Province, and the number of deaths to the virus stands at 45, it said, adding that infections have been recorded in 12 provinces and municipalities.

The CDC said it would be prepared for the virus' possible spreading in autumn and winter.
 
http://en.ce.cn/National/Local/201309/30/t20130930_1570892.shtml 

Sunday, September 29, 2013

WHO recommendation on influenza A(H7N9) vaccine virus

September 26, 2013
Since 31 March 2013, public health authorities in China have reported a total of 135 human cases of novel avian influenza A(H7N9) infection, including 44 deaths1. To date, there has been no evidence of sustained human-to-human transmission.
Because the A(H7N9) virus seems to transmit from animals to humans more readily than the highly pathogenic avian influenza A(H5N1) viruses, and little or no immunity against the novel virus A(H7N9) exists in the human population, WHO is actively working with its Member States and partners on effective responses and preparedness. As part of these efforts, candidate vaccine viruses2 are being developed and made available by the WHO GISRS.

To date, the HA sequences of 123 A(H7N9) viruses (54 viruses from 44 human cases and 69 avian/environmental viruses ) have been deposited in genetic sequence databases. Genetic analysis of the HA genes indicated limited heterogeneity among these viruses (see Figure). Antigenic analyses of 45 viruses from humans, animals and environment with post-infection ferret antisera indicated that the provisionally recommended vaccine virus, A/Anhui/1/2013- like virus3, elicits antibodies that react well with all viruses tested (see Table).

Based on genetic and antigenic analysis, it is recommended that:
- An A/Anhui/1/2013-like* virus be used for the development of influenza A(H7N9) vaccines for pandemic preparedness purposes.
* A/Shanghai/2/2013 is an A/Anhui/1/2013-like virus.

Status updates on the development and availability of influenza A(H7N9) candidate vaccine viruses4, as well as biosafety requirements5 on handling the A(H7N9) candidate vaccine viruses, are available on the WHO website.
The A(H7N9) viruses, including candidate vaccine viruses, are considered PIP Biological Materials and are being shared under the PIP Framework.6
For more information, please contact gisrs-whohq@who.int.

Continued:  http://www.who.int/influenza/human_animal_interface/influenza_h7n9/201309_h7n9_recommendation.pdf

Saturday, September 28, 2013

St. Louis Video Interview with Dr. Sharon Frey on Vaccine Work with #H7N9

 Video with Dr. Sharon Frey at link below

ST. LOUIS (KSDK) - There's a new flu pandemic brewing called H7N9. The first people to come down with it live in China, but the race to develop a vaccine is going on fast and furious right here in St. Louis.
You may be wondering how alarmed should you be, and how can you help, which is why we invited Dr. Sharon Frey to join First @ 4 Wednesday.
Dr. Frey is professor of infectious diseases at Saint Louis University School of Medicine and is heading up the work to find a vaccine.
Click the video player above to learn about how dangerous this strain of the flu is, and if it's a threat to St. Louisans.
If you'd like to volunteer for the study, call 314-977-6333 or e-mail vaccine@slu.edu  to find out more.

http://www.ksdk.com/news/article/399551/183/SLU-professor-heading-up-research-on-H7N9-vaccine

Government recruits volunteers for experimental bird flu vaccine

Excerpt - Editing is mine
September 27, 2013

Health officials are calling for 1,700 volunteers to enroll in a study of an experimental vaccine to fight bird flu (H7N9 avian influenza), according to the National Institutes of Health (NIH).

-snip-

So far, reports of H7N9 are primarily in China. According the NIH, the virus does not easily jump from person-to-person.
However, the health agency is concerned that the virus could mutate into a more problematic virus.

"H7N9 avian influenza virus...has the potential to cause widespread sickness and mortality," said Director Anthony S. Fauci, M.D at the National Institute of Allergy and Infectious Diseases (NIAID), a department of the NIH.

"We are now testing a vaccine candidate with and without adjuvant in an effort to prepare for and, hopefully, protect against this possibility."

-snip-

The study is comprised of two separate clinical trials. Together, the trials will enroll 1,700 healthy adults between the ages of 19 and 64 years old. A panel of independent experts will monitor safety throughout the trial, according to the NIH.
The H7N9 clinical trials are designed to gather information about:
  • safety of the candidate vaccine
  • immune responses at different doses
  • effects of adjuvants
Two different adjuvants will be tested along with the H7N9 vaccine itself. Those adjuvants include:
The H7N9 clinical trials will be conducted in the following cities:
  • Houston, Texas
  • Cincinnati, Ohio
  • Durham, North Carolina
  • Atlanta, Georgia
  • Seattle, Washington
  • Saint Louis, Missouri
  • Iowa City, Iowa
  • Baltimore, Maryland
  • Nashville, Tennessee




http://www.examiner.com/article/government-recruits-volunteers-for-experimental-bird-flu-vaccine

VVRP receives contract from NIH to continue its work as Vaccine & Treatment Evaluation Units

Excerpt - editing is mine
September 27, 2013

The Vanderbilt Vaccine Research Program (VVRP) has received a contract from the National Institutes of Health (NIH) to continue its work as one of the nation's Vaccine and Treatment Evaluation Units (VTEU). Vanderbilt is one of nine institutions that have the potential to receive funding up to $135 million per year from the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, over a seven-year period.

"This contract renewal is evidence of the importance of this work to public health on an international and national scale," said Kathryn Edwards, M.D., Sarah H. Sell and Cornelius Vanderbilt Professor of Pediatrics, and director of the VVRP.

-snip-

As a VTEU for the NIH, the VVRP has conducted trials to inform public policy twice in the last decade to address potential pandemic concerns: once to test and evaluate the H1N1 influenza vaccine at the start of the 2009 pandemic, and again just this month to evaluate a vaccine against a potential future pandemic threat from the H7N9 avian influenza.

Other research projects involve the testing of enhancements to the formulation of influenza vaccines to improve their protective power. The additives that are used to enhance flu vaccine are called "adjuvants."

"When these adjuvants are added to vaccines, they improve the responses and reduce the amount of vaccine needed," Edwards said. "This has proven to be particularly important in avian influenza vaccines which can lack the ability to adequately stimulate a protective response in our immune systems."

Edwards says adjuvants are also exciting because of their potential to help avoid vaccine shortages in the future. If an adjuvant makes a vaccine 20 times more potent, it allows manufacturers to stretch vaccine supplies into 20 times more doses.

"That might mean, in the case of pandemic flu, that we can protect our population and others in developing countries that do not have the potential to make vaccines," Edwards said.


http://www.news-medical.net/news/20130927/VVRP-receives-contract-from-NIH-to-continue-its-work-as-Vaccine-and-Treatment-Evaluation-Units.aspx